Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.
Scrip - June 15, 2026

Wave Neuroscience Wins FDA Clearance For Personalized Brain Stimulation For PTSD
Wave Neuroscience announced today it received US FDA clearance for MeRT, a personalized TMS therapy that maps individual brainwave patterns via EEG to treat PTSD.
Medtech Insight - June 12, 2026

International Device Nomenclature Agency Calls On Regulators To Require GMDN Terms In Submissions
A new guide from the Global Medical Device Nomenclature Agency instructs regulators on the best approach for implementing the standardized device-naming system. The document calls for regulators to request GMDN Terms, as well as UDIs, in device submissions.
Medtech Insight - June 12, 2026

Latest FTC Target Of False Supplement Ad Claims Complaint Alleged To Be Repeat Offender
“Amare’s misconduct is particularly egregious” because its “leadership has included two key players already subject to prior court-ordered permanent injunctions prohibiting them from making false, misleading, or unsubstantiated claims,” according to FTC complaint.
HBW Insight - June 15, 2026

Livzon Gains Chinese Approval For Fertility Biosimilar
Livzon MABPharm has announced approval from China’s National Medical Products Administration for its recombinant human follitropin alfa solution for injection.
Generics Bulletin - June 12, 2026

Sanofi And Regeneron Signal ‘Vigorous’ Patent Defense Plans For Dupixent
Regeneron’s CFO Christopher Fenimore has outlined intentions to “extend Dupixent's marketing exclusivity for as long as we can,” as the list of upcoming biosimilar competitors keeps growing.
Generics Bulletin - June 12, 2026

Xbrane Bets On Partners To Unlock Darzalex Biosimilar
Xbrane has partnered with JOINN Biologics US to advance Xdarzane, its proposed Darzalex biosimilar, shifting further CMC and pilot-scale work to a specialist manufacturer as the Swedish developer pursues a capital-light strategy built around partnerships, licensing and retained upside.
Generics Bulletin - June 12, 2026

Streamlining Alone Will Not Fill Europe’s Biosimilar Void
Representatives from Medicines for Europe and its Biosimilar Medicines Group tell Generics Bulletin that Europe’s move away from routine comparative efficacy studies is a major step forward but not enough on its own to solve the looming biosimilar “void.”
Generics Bulletin - June 12, 2026

Fragile Scaling: The Hidden Risks When Biotech Cuts Its Way To Survival
While layoffs are treated most often as a financial lever, they are also a legal, operational and governance event that most biotechs fail to manage as such.
In Vivo - June 12, 2026